EA
BMRN icon

Edge Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Edge Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-28
Closed -$2K – 830
2018
Q1 		$2K Hold
28
– – ﹤0.01% 789
2017
Q4 		$2K Hold
28
– – ﹤0.01% 846
2017
Q3 		$2K Buy
+28
New +$2.47K ﹤0.01% 807

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Edge Advisors's BMRN Position: Q2 2018 in Review

Edge Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 28 shares — an estimated $2K sold.

Edge Advisors first reported a position in BMRN in Q3 2017 and held it in 3 quarters. The position peaked at $2K in Q1 2018. 448 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • Edge Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Edge Advisors sold 28 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $2K.
  • Edge Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Edge Advisors's BioMarin Pharmaceuticals position peaked at $2K in Q1 2018.
  • 448 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.